Does Depot Medroxyprogesterone Block Ovulation in Extremely Obese Women?

Obese women did not ovulate >1 week after receiving DMPA, but some showed evidence of follicular development.

Data about the efficacy of hormonal contraceptives in obese women are sparse. To assess the effects of subcutaneous depot medroxyprogesterone acetate (DMPA-SC) on ovulation in extremely obese women (body-mass index, ≥40.0 kg/m²), U.S. researchers assessed circulating levels of medroxyprogesterone acetate (MPA), estradiol (E2), and progesterone (P4) at regular intervals for 26 weeks following administration of 104-mg DMPA-SC at baseline and 12 weeks in five normal-weight (BMI, 18.5–24.9), five obese (BMI, 30.0–39.9), and five extremely obese (BMI, ≥40.0) women.

Only one woman in each group showed hormonal evidence of ovulation during the week after the first DMPA-SC injection, and no participants showed evidence of ovulation >1 week postinjec…

Reviewing Author

Robert W. Rebar, MD

Disclosures

Consultant/Advisory BoardMyovant Sciences, Inc.

Editorial BoardsEndoText; Clinical OB/GYN Alert

Leadership Positions in Professional SocietiesAmerican Society for Reproductive Medicine (Member, Ethics Committee)

Robert W. Rebar, MD

Disclosures

Consultant/Advisory BoardMyovant Sciences, Inc.

Editorial BoardsEndoText; Clinical OB/GYN Alert

Leadership Positions in Professional SocietiesAmerican Society for Reproductive Medicine (Member, Ethics Committee)

Does Depot Medroxyprogesterone Block Ovulation in Extremely Obese Women?

Topics

Reviewing Author